A list of in vitro assays can test the interaction of nanoparticles with the immune system, which include assays for hemolysis, platelet aggregation, plasma coagulation, complement activation, plasma protein binding, phagocytosis, CFU-GM, leukocyte proliferation, nitric oxide production by macrophages, and chemotaxis (81).
Biocompatibility of the micelles was proved by the blood component aggregation and plasma protein interaction studies.
Hemorheological parameters including erythrocyte deformability, erythrocyte aggregation and plasma viscosity were measured before and after 2 months therapy with strontium ranelate.
Taken together, these results suggest that aggregation of plasma Fn by BBK32 or anastellin involves similar types of conformational changes in the glycoprotein and that these conformational changes are not limited to the 1 3F3 region but extend towards the C-terminus of the protein.
Although the physiological mechanisms accounting for this benefit remain incompletely defined, animal studies and human intervention studies have identified many relevant effects – for example, supplementation of quercetin may reduce platelet aggregation and plasma concentrations of atherogenic oxidised LDL (oxLDL).
The intravenously injected DiR-PLA NPs/MMC was rapidly cleared from the systemic circulation; the fluorescence signal of the DiR-PLA NPs/MMC in the blood was hardly detectable in as little as 0.5 h after the intravenous injection, which was expected based on their rapid aggregations in plasma.
Finally, the [Ca2+]o-dependence of ADP-evoked aggregation responses in plasma was abolished when platelets were resuspended in autologous heat-treated plasma (60°C, 30 min) to destroy enzymatic activity (Fig 2C, D; 41·1 ± 1·1 and 41·5 ± 1·9% in millimolar versus micromolar [Ca2+]o respectively).
Again, we observed better margination in aggregating samples (plasma, Dextran), but high shear rates inhibited aggregation and margination.
Main Outcome Measure: Platelet adhesiveness on fibrinogen-coated surface and epinephrine-induced aggregation in vitro, plasma soluble P-selectin (sP-selectin), and urinary 6-keto-prostaglandin F1α (6-keto PGF1α) levels.
Further analysis of this interaction showed that BBK32 can cause the aggregation of human plasma Fn in a similar concentration-dependent manner to that of anastellin, the superfibronectin (sFn) inducing agent.
All fractions were tested on collagen-, ristocepinephrine-,hrine-, or ADP-induced platelet aggregation in human plasma.
